The company is set to start Phase 1 physician-led clinical trials to ensure that the drug is safe. Testing will start with 30 healthy male adults who are unlikely to grow more teeth even if the drug works. If all goes well, plans are to move on in 2025 to Phase 2 trials gauging effectiveness, with the treatment administered to patients aged 2 to 7 with congenital anodontia. Toregem hopes to offer the antibody drug for 1.5 million JPY (USD9,800) and have it covered by health insurance.